Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury

McEuen, Kristin, Borlak, Jürgen, Tong, Weida, Chen, Minjun·2017·International Journal of Molecular Sciences

Abstract

Drug-induced liver injury (DILI), although rare, is a frequent cause of adverse drug reactions resulting in warnings and withdrawals of numerous medications. Despite the research community’s best efforts, current testing strategies aimed at identifying hepatotoxic drugs prior to human trials are not sufficiently powered to predict the complex mechanisms leading to DILI. In our previous studies, we demonstrated lipophilicity and dose to be associated with increased DILI risk and, and in our latest work, we factored reactive metabolites into the algorithm to predict DILI. Given the inconsistency in determining the potential for drugs to cause DILI, the present study comprehensively assesses the relationship between DILI risk and lipophilicity and the extent of metabolism using a large published dataset of 1036 Food and Drug Administration (FDA)-approved drugs by considering five independent DILI annotations. We found that lipophilicity and the extent of metabolism alone were associated with increased risk for DILI. Moreover, when analyzed in combination with high daily dose (≥100 mg), lipophilicity was statistically significantly associated with the risk of DILI across all datasets (p < 0.05). Similarly, the combination of extensive hepatic metabolism (≥50%) and high daily dose (≥100 mg) was also strongly associated with an increased risk of DILI among all datasets analyzed (p < 0.05). Our results suggest that both lipophilicity and the extent of hepatic metabolism can be considered important risk factors for DILI in humans, and that this relationship to DILI risk is much stronger when considered in combination with dose. The proposed paradigm allows the convergence of different published annotations to a more uniform assessment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms18071335

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 30

  1. Amacher, 2012, The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury, Expert Opin. Drug Metab. Toxicol., 8, 335, 10.1517/17425255.2012.658041 · DOI
  2. Fontana, 2014, Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives, Gastroenterology, 146, 914, 10.1053/j.gastro.2013.12.032 · DOI · Paper page
  3. Chen, 2015, Drug-induced liver injury: Interactions between drug properties and host factors, J. Hepatol., 63, 503, 10.1016/j.jhep.2015.04.016 · DOI · Paper page
  4. Daly, 2009, HLA-b* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat. Genet., 41, 816, 10.1038/ng.379 · DOI · Paper page
  5. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
  6. Monshi, 2013, Human leukocyte antigen (HLA)-B* 57: 01-Restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI · Paper page
  7. Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J. Hepatol., 53, 1049, 10.1016/j.jhep.2010.05.033 · DOI
  8. Spraggs, 2011, HLA-DQA1* 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
  9. Leise, M.D., Poterucha, J.J., and Talwalkar, J.A. (2014). Drug-induced liver injury. Mayo Clinic Proceedings, Elsevier. · DOI
  10. Lauschke, V.M., and Ingelman-Sundberg, M. (2016). The importance of patient-specific factors for hepatic drug response and toxicity. Int. J. Mol. Sci., 17. · DOI
  11. Borlak, 2013, Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury, Genome Med., 5, 86, 10.1186/gm493 · DOI
  12. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  13. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  14. Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI · Paper page
  15. Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
  16. Chen, H., and Boutros, P.C. (2011). Venndiagram: A package for the generation of highly-customizable Venn and Euler diagrams in r. BMC Bioinform., 12. · DOI · Paper page
  17. Greene, 2010, Developing structure—Activity relationships for the prediction of hepatotoxicity, Chem. Res. Toxicol., 23, 1215, 10.1021/tx1000865 · DOI · Paper page
  18. Zhu, 2014, Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data, Toxicology, 321, 62, 10.1016/j.tox.2014.03.009 · DOI
  19. Sakatis, 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds, Chem. Res. Toxicol., 25, 2067, 10.1021/tx300075j · DOI
  20. Xu, 2008, Cellular imaging predictions of clinical drug-induced liver injury, Toxicol. Sci., 105, 97, 10.1093/toxsci/kfn109 · DOI · Paper page
  21. Kaplowitz, 2013, Avoiding idiosyncratic DILI: Two is better than one, Hepatology, 58, 15, 10.1002/hep.26295 · DOI
  22. Danan, 2015, RUCAM in drug and herb induced liver injury: The update, Int. J. Mol. Sci., 17, 14, 10.3390/ijms17010014 · DOI · Paper page
  23. Lewis, 2014, Causality assessment: Which is best—Expert opinion or rucam?, Clin. Liver Dis., 4, 4, 10.1002/cld.365 · DOI · Paper page
  24. Lucena, 2008, Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury, Aliment. Pharmacol. Ther., 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
  25. Björnsson, E.S. (2016). Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci., 17. · DOI · Paper page
  26. Teschke, 2014, Drug induced liver injury: Accuracy of diagnosis in published reports, Ann. Hepatol., 13, 248, 10.1016/S1665-2681(19)30888-9 · DOI
  27. Weng, 2015, A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications, Oncotarget, 6, 17031, 10.18632/oncotarget.4400 · DOI
  28. Ortega-Alonso, A., Stephens, C., Lucena, M.I., and Andrade, R.J. (2016). Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci., 17. · DOI
  29. Corsini, 2013, Drug-induced liver injury: The role of drug metabolism and transport, J. Clin. Pharmacol., 53, 463, 10.1002/jcph.23 · DOI · Paper page
  30. Suzuki, 2010, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™, Drug Saf., 33, 503, 10.2165/11535340-000000000-00000 · DOI · Paper page

Cited by

See all 62

Metadata

Authors
McEuen, K., Borlak, J., Tong, W., & Chen, M.
Affiliations
  • Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA
  • Center of Pharmacology and Toxicology, Hannover Medical School, Hannover 30625, Germany
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-06-22
Volume
18
Issue
7
Pages
1335
ISSN
1422-0067
Cited by
62
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. https://app.cochat.ai/papers/10.3390/ijms18071335
The paper
McEuen, K., Borlak, J., Tong, W., & Chen, M. (2017). Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18071335

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.